. 2019 Nov 1;10(Suppl 4):4–8. doi: 10.6004/jadpro.2019.10.8.12

Table 2. Risk Stratification Based on Cytogenetics and Molecular Abnormalities.

Risk status	Cytogenetics	Molecular abnormalities
Favorable risk	t(8;21)(q22;q22.1); RUNX1-RUNX1T1	Biallelic mutated CEBPA
Favorable risk	inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Mutated NPM1 without FLT3-ITD or with FLT3-ITD^low
Intermediate risk	t(9;11)(p21.3;q23.3); MLLT3-KMT2A	Mutated NPM1 and FLT3-ITD^high
Intermediate risk	Others not classified as favorable or adverse	Wild-type NPM1 without FLT3-ITD or with FLT3-ITD^low (without adverse-risk genetic lesions)
Poor risk	t(6;9)(p23;q34.1); DEK-NUP214	Wild-type NPM1 and FLT3-ITD^high
	t(v;11q23.3); KMT2A rearranged	Mutated RUNX1
	t(9;22)(q34.1;q11.2); BCR-ABL1	Mutated ASXL1
	inv(3)(q21.3q26.2) or t(3;3) (q21.3;q26.2); GATA2,MECOM(EVI1)	Mutated TP53
	-5 or del(5q); -7; -17/abn(17p)
	Complex karyotype; monosomal karyotype

Note. Information from NCCN (2019).